Attovia Therapeutics annual ebitda
2024
2025
Attovia Therapeutics EBITDA Growth & History (ATTO)
Attovia Therapeutics's calculated EBITDA was −$66.4M for fiscal 2025.
View full Attovia Therapeutics company overviewAttovia Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$66.4M | −$25.1M | — |
| 2024 | 2024-12-31 | −$41.2M | — | — |
Attovia Therapeutics quarterly ebitda
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$21.6M | −$5.2M | — |
| Q1 2026 | 2026-03-31 | −$19.7M | −$3.8M | — |
| Q2 2025 | 2025-06-30 | −$16.4M | — | — |
| Q1 2025 | 2025-03-31 | −$16.0M | — | — |
Attovia Therapeutics ebitda trends
Between the periods ended 2024-12-31 and 2025-12-31, Attovia Therapeutics's ebitda decreased from −$41.2M to −$66.4M, a change of −$25.1M. The latest reported quarter, Q2 2026, shows −$21.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Attovia Therapeutics source filings ↗